A new landmark decision has been made which will have a staggering effect in the field of Huntington’s disease. So, there has been a grant of a patent to VistaGen Therapeutics Inc. for the drug AV-101 which can be used for the treatment of disorders like Parkinson’s disease, levodopa-induced dyskinesia, and Major Depressive Disorder. The patent has been granted for the treatment of these diseases in countries like France, Denmark, Ireland, Germany, Italy, Switzerland, Spain, Portugal and the United Kingdom.
This patent has been granted by the European Patent Office (EPO). This patent is going to be in continuance until the year 2034. Now, this drug is in Phase 2 trials. So, this drug is getting evaluated for its efficacy i.e. whether it’s going to deliver the results as promised. As per Shawn Singh who is the CEO of the company VistaGen, working on this drug, “We are pleased that the EPO has now granted significant CNS-related patent claims for AV-101, another major step forward in our highly focused efforts to secure intellectual property protection for AV-101 for depression and other CNS indications.” AV-101 will be given to patients through oral means i.e. via the mouth.
The study of this drug is getting financed by the organization of U.S. National Institute of Mental Health. The one who is responsible for the research is Dr. Carlos Zarate Jr., who is the Chief of Neurobiology and Treatment of Mood Disorders department. He is also the head of the branch of the Experimental Therapeutics and Pathophysiology where he works as a principal investigator. In the phase 2 trials of this drug, 180 patients are going to be evaluated.
So, all these patients who have been chosen for the study are suffering from MDD and have not responded sufficiently to the antidepressants approved by FDA. Dr. Maurizio Fava who hails from Harvard University is also going to participate in this research as principal investigator. Apart from MDD, this drug will treat patients who are suffering from different disorders all affecting the brain such as neuropathic pain, Huntington’s disease, and epilepsy. This drug will ensure that the NDMA receptors are controlled inside the brain.
AMPA pathways are activated and achieve therapeutic effects of AV-101 are achieved. Major depressive disorder refers to depression, which has the patient suffering from low mood for a period of 2 weeks mandatorily. In this disorder, the bouts of depression may occur after years, but in some others, the phase of depression is constantly present throughout.